An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma
Completed · Phase 2 · NCT03601078
Conditions: Multiple Myeloma
At a glance
- Research payments reported, 2025
- $3.9M
- U.S. investigators named
- 18
- Sites paid
- 17
- Planned or actual enrollment
- 312
About the trial
- Sponsor
- Celgene
- Tested
- bb2121 (biological), Lenalomide (drug), Talquetamab (drug)
- Dates
- Started 2018-12-13; completion 2026-01-15
- Results posted
- Not yet
This study is a multi-cohort, open-label, multicenter Phase 2 study to evaluate the efficacy and safety of bb2121 in participants with relapsed and refractory multiple myeloma (RRMM) (Cohort 1), in participants with RRMM who receive bridging therapy with talquetamab (Cohort 1b), in participants with multiple myeloma (MM) having progressed within 18 months of initial treatment with autologous stem cell transplantation (ASCT) (Cohort 2a) and without ASCT (Cohort 2b) or, in participants with inadequate response post ASCT during initial treatment (Cohort 2c) and the efficacy and safety of bb2121 used in combination with lenalidomide maintenance in participants with suboptimal response post AS…
From ClinicalTrials.gov, last updated 2026-03-04. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Celgene Corporation reported $3.9M in research payments for this study in 2025 (19 payments).
Products named: Abecma
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Peter L. Bergsagel, M.D. Hematology & Oncology · Scottsdale, AZ
- Alfred Chung Hematology · San Francisco, CA
- Adam S. Sperling, MD, PHD Hematology · Stanford, CA
- Melissa Alsina, MD Hematology · Tampa, FL
- David E. Avigan, M.D. Hematology & Oncology · Boston, MA
- Noopur S. Raje, MD Medical Oncology · Boston, MA
- Ravi Vij, MD Medical Oncology · Saint Louis, MO
- Barry A. Paul, MD Hematology · Charlotte, NC
- Christopher R. D'angelo, M.D. Hematology · Omaha, NE
- David S. Siegel, MD Medical Oncology · Hackensack, NJ
- Ran Reshef, MD Hematology · New York, NY
- Shambavi D. Richard, M.D., Hematology & Oncology · New York, NY
- Jesus G. Berdeja, M.D. Hematology & Oncology · Nashville, TN
- Larry D. Anderson JR., M.D. , PHD Medical Oncology · Dallas, TX
- Meera Mohan, M.D Medical Oncology · Houston, TX
- Krina K. Patel, M.D. Internal Medicine · Houston, TX
- Madhav V. Dhodapkar, MD Hematology & Oncology · Seattle, WA
- Daniel N. Egan, MD Hematology & Oncology · Seattle, WA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Dana-Farber Cancer Institute $1.2M
- Ut MD Anderson Cancer Center $719,163
- University of Texas Southwestern $378,940
- Washington University $320,081
- Carolinas Medical Center-Northeast, NC $232,929
- Moffitt Cancer Center $185,848
- Mount Sinai School of Medicine $177,875
- UCSF Langley Porter Psychiatric Hospital and Clinics, CA $122,301
- Hackensack University Medical Center, NJ $118,530
- Medical College of Wisconsin, Incorporated $109,938
- The Trustees of Columbia University in The City of New York $78,793
- Mayo Clinic Hospital, AZ $69,742
- Emory University Hospital, GA $62,813
- Tennessee Oncology, PLLC $17,881
- Unehealth $11,934
- Swedish Medical Center, WA $8,839
- Sarah Cannon Research Institute, Llc $8,111
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.